Beta-agonists alternatives market seen growing to $2.81 billion by 2030

The beta-agonists alternatives market is projected to rise from $2.08 billion in 2026 to $2.81 billion by 2030, according to The Business Research Company. Growth is being fueled by rising asthma cases, higher healthcare spending, and demand for safer respiratory therapies.

Why it matters: - The market is expanding as more patients and clinicians look for respiratory treatments that avoid the limits and side effects of conventional beta-agonists. - Demand is tied to asthma, COPD and other airway diseases that need safer long-term control options. - The shift could lift adoption of anticholinergics, corticosteroids, biologics and other non-beta receptor therapies.

What happened: - The Business Research Company projected the beta-agonists alternatives market will grow from $1.93 billion in 2025 to $2.08 billion in 2026. - The report forecasts the market will reach $2.81 billion by 2030, implying a 7.9% CAGR over the forecast period. - North America was the largest regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region through 2030.

The details: - Beta-agonists alternatives include drugs and therapies used when traditional beta-adrenergic agonists are contraindicated, poorly tolerated or less effective. - Common options include anticholinergic agents, corticosteroids and other non-beta receptor therapies. - Historical growth was supported by beta-agonist monotherapy in asthma, rising respiratory disease cases, wider use of anticholinergic drugs such as Ipratropium, increased use of inhaled corticosteroids and growth in hospital respiratory care programs. - The report said future growth will be driven by precision respiratory medicine, safer long-acting bronchodilators, biologic therapies for severe asthma and COPD, home-based respiratory care and combination therapy development. - Emerging trends include non-beta receptor bronchodilators, combination inhalation treatments, personalized respiratory regimens, longer-term steroid-based inflammation control and herbal or plant-derived remedies for mild asthma and bronchospasm. - The report links asthma prevalence to market demand because the disease narrows airways and can cause wheezing, coughing, chest tightness and shortness of breath. - The National Asthma Council of Australia reported 474 asthma-related deaths in 2023, nearly unchanged from 473 in 2022. - The report also points to rising healthcare spending as a catalyst. - US healthcare expenditures rose 7.5% in 2023 to $4.9 trillion, or about $14,570 per person, according to the Centers for Medicare and Medicaid Services. - The report says aging populations are adding to demand because older adults often need respiratory treatments with lower cardiovascular risk and better long-term tolerance. - In the UK, 12.7 million people aged 65 or older lived in the country in 2022, equal to 19% of the population, and that share is projected to rise to 27% by 2072.

Between the lines: - The forecast points to a respiratory market moving away from one-size-fits-all rescue therapy and toward more tailored maintenance treatment. - The emphasis on safer long-acting options suggests clinicians and drug makers are focused on chronic management, not just symptom relief. - The inclusion of herbal and plant-derived remedies shows the market is broadening beyond standard prescription categories.

What's next: - The report expects broader adoption of home-based respiratory care and combination therapies to keep supporting growth through 2030. - Regional gains in Asia-Pacific could narrow the gap with North America if current adoption trends continue. - Product development is likely to focus on tolerability, precision treatment and severe-disease biologics.

The bottom line: - The beta-agonists alternatives market is set for steady expansion, with demand shaped by asthma prevalence, aging populations and a push for safer respiratory therapies.

More information